PSP Brainstem Degeneration

PSP Brainstem Degeneration

Overview

Progressive Supranuclear Palsy (PSP) is characterized by prominent brainstem degeneration, particularly affecting the midbrain, which underlies many of the disease's distinctive clinical features. Understanding the pattern and mechanisms of brainstem involvement is essential for diagnosis and therapeutic development. PMID: 40399058

Overview

PSP exhibits a characteristic pattern of brainstem pathology:

• Midbrain: Most severely affected, with classic "hummingbird" sign on MRI
• Pons: Moderate involvement, particularly in variant PSP
• Medulla: Variable, with dorsal motor nucleus prominently affected
• Subthalamic nucleus: Severe tau pathology, contributes to dysautonomia

The brainstem degeneration in PSP follows a characteristic anatomical distribution that helps distinguish it from other parkinsonian disorders. PMID: 39876539

Midbrain Pathology

Anatomical Features

The midbrain in PSP shows:

Substantia nigra pars compacta

• Severe neuronal loss (60-80%)
• Neurofibrillary tangles (NFTs)
• Globose tangles, not classic Lewy bodies

Red nucleus

• Tau pathology in neurons
• Glial involvement

Superior colliculus

• Involvement correlates with vertical gaze palsy

Periaqueductal gray

• Tau pathology
• Contributes to gait/falls

The Hummingbird Sign

The characteristic MRI finding reflects:

```mermaid
flowchart TD
A["Midbrain Atrophy"] --> B["Tectal Plate Flattening"]
A --> C["Pons Preservation Relative"]
A --> D["Aqueduct Elongation"]

...

PSP Brainstem Degeneration

Overview

Progressive Supranuclear Palsy (PSP) is characterized by prominent brainstem degeneration, particularly affecting the midbrain, which underlies many of the disease's distinctive clinical features. Understanding the pattern and mechanisms of brainstem involvement is essential for diagnosis and therapeutic development. PMID: 40399058

Overview

PSP exhibits a characteristic pattern of brainstem pathology:

• Midbrain: Most severely affected, with classic "hummingbird" sign on MRI
• Pons: Moderate involvement, particularly in variant PSP
• Medulla: Variable, with dorsal motor nucleus prominently affected
• Subthalamic nucleus: Severe tau pathology, contributes to dysautonomia

The brainstem degeneration in PSP follows a characteristic anatomical distribution that helps distinguish it from other parkinsonian disorders. PMID: 39876539

Midbrain Pathology

Anatomical Features

The midbrain in PSP shows:

Substantia nigra pars compacta

• Severe neuronal loss (60-80%)
• Neurofibrillary tangles (NFTs)
• Globose tangles, not classic Lewy bodies

Red nucleus

• Tau pathology in neurons
• Glial involvement

Superior colliculus

• Involvement correlates with vertical gaze palsy

Periaqueductal gray

• Tau pathology
• Contributes to gait/falls

The Hummingbird Sign

The characteristic MRI finding reflects:

The "hummingbird" or "penguin" sign reflects:

• Severe midbrain atrophy
• Relative pontine preservation
• Loss of the typical midbrain-pons junction

Pontine Involvement

Patterns of Degeneration

The pons shows distinct involvement:

| Structure | Pathology | Clinical Correlation |
|-----------|-----------|---------------------|
| Pontine nuclei | Neuronal loss, NFTs | Cognitive dysfunction |
| Basis pontis | Corticopontine tract degeneration | Gait impairment |
| Locus coeruleus | Moderate NFT burden | Neuropsychiatric symptoms |
| Raphe nuclei | Serotonergic neuron loss | Depression |

Variant PSP Patterns

Different PSP subtypes show varying pontine involvement:

• PSP-P: Less pontine involvement
• PSP-CBS: Moderate pontine involvement
• PSP-PAGF: Prominent pontine atrophy

Medullary Degeneration

Dorsal Motor Nucleus

The dorsal motor nucleus of the vagus shows:

• Severe tau pathology
• Autonomic dysfunction correlation
• Early involvement in PSP progression

Other Medullary Structures

• Inferior olive: Involvement in PSP-P
• Cranial nerve nuclei: Variable
• Corticospinal tracts: Degeneration contributes to spasticity

Subthalamic Nucleus

Key Structure in PSP

The subthalamic nucleus (STN) is prominently affected in PSP:

• High tau burden
• Globose NFTs
• Contributes to:
• Dyskinesias (if treated with levodopa)
• Falls
• Cognitive dysfunction

See: [PSP basal ganglia circuits](/diseases/progressive-supranuclear-palsy)

Neurotransmitter Correlates

Dopaminergic Deficits

• Substantial nigral loss
• Contributes to parkinsonism
• Explains limited levodopa response

Other Neurotransmitters

| System | Brainstem Site | Clinical Impact |
|--------|---------------|-----------------|
| Noradrenergic | Locus coeruleus | Depression, attention |
| Serotonergic | Raphe nuclei | Mood, sleep |
| Cholinergic | Pedunculopontine nucleus | Gait, falls |

See: [PSP neurotransmitter dysfunction](/mechanisms/neurotransmitter-dysfunction-psp)

Clinical Correlations

Vertical Gaze Palsy

The characteristic vertical gaze palsy results from:

Superior colliculus involvement

PPRF (paramedian pontine reticular formation)

IIIrd nerve nucleus degeneration

Early Falls

Brainstem involvement contributes to falls through:

• Midbrain reticular formation dysfunction
• Vestibular nucleus involvement
• Postural reflex impairment

Dysphagia

Medullary involvement causes:

• Bulbar palsy features
• Aspiration risk
• Mortality correlation

Diagnostic Implications

MRI Findings

| Finding | Region | Sensitivity |
|---------|--------|-------------|
| Hummingbird sign | Midbrain | 70-90% |
| MR parkinsonism index | Midbrain/pons | High specificity |
| Hot cross bun | Pons (variable) | Less than MSA |
| Third ventricle dilation | Midbrain | Correlates with disease |

Differential Diagnosis

Brainstem pattern helps distinguish:

• PSP vs PD: Midbrain atrophy absent in PD
• PSP vs MSA: Hot cross bun sign MSA-specific
• PSP vs CBD: More midbrain involvement in PSP

Therapeutic Implications

Current Approaches

• Levodopa: Limited response
• Botulinum toxin: For blepharospasm
• Speech therapy: For dysphagia
• Physical therapy: For falls

Emerging Targets

| Target | Approach | Rationale |
|--------|----------|------------|
| Tau reduction | Immunotherapy | Remove tau pathology |
| Neuroprotection | Disease-modifying | Protect neurons |
| Circuit modulation | Deep brain stimulation | STN/PPRN targeting |

Research Directions

Biomarkers

• MRI volumetric analysis: Quantitative midbrain measures
• CSF tau: Total and phosphorylated
• PET ligands: Tau imaging

Neuropathology Studies

• Understanding the anatomical progression
• Correlating burden with clinical features
• Identifying vulnerable neuronal populations

Recent Research Findings (2024-2025)

Midbrain-Specific Tau Pathology

Recent studies reveal unique aspects of midbrain involvement in PSP:

• Tau strain specificity: Cryo-EM shows PSP tau filaments have distinct protofilament arrangements
• Substantia nigra vulnerability: Ventral tier dopaminergic neurons preferentially affected
• Superior colliculus involvement: Tau burden correlates with vertical gaze palsy severity

Brainstem Volume Measurements

Advanced MRI allows precise measurement:
| Region | Volume Change | Correlation |
|--------|--------------|-------------|
| Midbrain | 25-35% reduction | Disease duration, severity |
| Pons | 15-20% reduction | Axial symptoms |
| Medulla | 10-15% reduction | Dysphagia, dysautonomia |

Neurotransmitter System Interactions

• Dopamine-norepinephrine: LC loss exacerbates SNc degeneration
• Serotonin-GABA: Raphe degeneration contributes to excessive GPi output
• Cholinergic PPN: PPN degeneration correlates with early gait impairment

Brainstem-Cortical Network Dysfunction

• Salience network: Brainstem nuclei are critical nodes
• Default mode network: Reduced midbrain-MPFC connectivity
• Motor network: Early brainstem involvement leads to compensatory cortical changes

Clinical-Biological Correlates

| Feature | Correlate | Finding |
|---------|-----------|---------|
| Early falls | Midbrain/pons ratio | High sensitivity PSP vs PD |
| Vertical gaze palsy | SC tau | PET ligand correlation |
| Dysphagia | Medulla volume | Predicts survival |
| Cognitive decline | Thalamic connectivity | fMRI biomarker |

Therapeutic Implications

• Tau immunotherapy: Anti-tau antibodies show promise for brainstem tau
• Exosome biomarkers: Brainstem-derived exosomes show distinct tau species
• Gene therapy: AAV vectors targeting brainstem nuclei in development

Brainstem-Specific Vulnerabilities in PSP

Regional Tau Propagation Patterns

Recent studies reveal brainstem-specific tau propagation patterns:

Cell-Type Specific Vulnerability

| Cell Type | Vulnerability | Consequences |
|-----------|---------------|--------------|
| Dopaminergic (SNc) | Severe (60-80% loss) | Parkinsonism |
| Cholinergic (PPN) | Moderate (40-60%) | Gait dysfunction |
| Noradrenergic (LC) | Moderate (40-50%) | Neuropsychiatric |
| Serotonergic (Raphe) | Variable | Mood, sleep |
| Motor (III, IV nuclei) | Severe | Gaze palsy |

Inter-Structural Connectivity

Brainstem structures show differential vulnerability based on connectivity:

• High-connectivity hubs: STN, PPN most vulnerable
• Primary entry points: SNc shows earliest tau deposition
• Relay stations: Superior colliculus receives convergent input

Emerging Biomarkers

MRI-Based Markers

| Metric | Application | PSP Specificity |
|--------|-------------|-----------------|
| Midbrain/pons ratio | Diagnostic | High |
| MRPI2 | Disease staging | Moderate |
| SCP area | Falls prediction | High |
| Third ventricle width | Cognitive decline | Moderate |

CSF and Blood Biomarkers

• Neurofilament light chain (NfL): Correlates with brainstem atrophy
• Total tau: Elevated in PSP vs PD
• Phospho-tau (181): Ratio differences from AD
• Brainstem-derived exosomes: Tau species analysis

Clinical Trials Targeting Brainstem

| Agent | Target | Stage | Outcome |
|-------|--------|-------|---------|
| Gosuranemab | Anti-tau antibody | Phase 2 | Pending |
| Tilavonemab | Anti-tau antibody | Phase 2 | Ongoing |
| Lithium | GSK3β inhibition | Phase 1/2 | Safety concern |
| AAV-GAD | Gene therapy (STN) | Phase 1 | Completed |

Brainstem Tau Phosphorylation Patterns

Region-Specific Kinase and Phosphatase Activity

The pattern of tau phosphorylation in PSP brainstem differs from cortical regions: PMID: 38506619

| Kinase | Activity | Region |
|--------|----------|--------|
| GSK-3β | Increased | SN, STN |
| CDK5 | Increased | Midbrain |
| MARK4 | Elevated | Pontine |
| PP2A | Decreased | All regions |

Phospho-Tau Epitopes in Brainstem

PSP brainstem shows characteristic phospho-tau epitopes:

• AT8: Strong positivity in SN, STN, LC
• AT100: Correlates with NFT progression
• Ser356: PSP-specific marker, abundant in brainstem
• Ser262: Early marker, transport-related vulnerability

Vestibular and Oculomotor Integration

Midbrain Oculomotor Circuit

The oculomotor pathway in PSP shows characteristic vulnerability:

Vestibular Nuclei Involvement

The vestibular system is specifically affected in PSP:

• Superior vestibular nucleus: Early involvement
• Medial vestibular nucleus: Correlates with postural instability
• Lateral vestibular nucleus: Contributes to falls risk
• Descending vestibular nucleus: Dysphagia correlation

Square Wave Jerks and Microsaccades

The distinctive square wave jerks in PSP result from:

SC tau pathology disrupting saccade generation

Burst neuron dysfunction in the pontine paramedian reticular formation (PPRF)

Impaired saccadic inhibition from basal ganglia output

Pontine Raphe and Neuropsychiatric Features

Raphe nuclei involvement in PSP

The median and dorsal raphe nuclei show substantial tau pathology:

| Raphe Subdivision | Tau Burden | Clinical Correlation |
|-------------------|------------|---------------------|
| Dorsal raphe (DRN) | Severe | Depression, sleep |
| Median raphe (MRN) | Moderate | Anxiety, circadian |
| Nucleus raphe pontis | Moderate | Motor coordination |

Serotonergic System Impact

• DRN neuronal loss: Correlates with early depression in PSP
• Tryptophan hydroxylase (TPH2) reduction: Found in PSP brainstem
• 5-HT1A receptor changes: Observed in PSP midbrain PET studies
• Therapeutic implications: SSRI response patterns in PSP

Circadian Rhythm Disruption

Brainstem raphe involvement contributes to:

• Sleep fragmentation (LC + raphe dual involvement)
• REM sleep behavior disorder (overlapping with PD features)
• Body temperature dysregulation
• Daytime somnolence from arousal system failure

Medullary Integration and Autonomic Dysfunction

Cardiovagal Involvement

The dorsal motor nucleus of the vagus (DMNX) and nucleus ambiguus show:

• Severe tau pathology: Neuronal loss up to 50%
• NTS (nucleus tractus solitarius) involvement: Baroreflex impairment
• Clinical correlations: Orthostatic hypotension, supine hypertension
• Overlap with MSA-P: PSP-DMV correlation, but distinct from MSA

Respiratory Control Centers

Medullary respiratory centers affected in PSP:

• Pre-Botzinger complex: Breathing rhythm generation
• Retrotrapezoid nucleus (RTN): Chemosensitivity
• Dorsal respiratory group: Integration of afferent input
• Ventral respiratory column: Voluntary breathing control

Clinical manifestations:

• Dysregulated breathing patterns during sleep
• Reduced ventilatory responses to hypoxia/hypercapnia
• Aspiration risk from impaired laryngeal protection
• Sudden death risk from brainstem cardiorespiratory failure

Inferior Olivary Degeneration

The inferior olivary nucleus shows distinctive pathology in PSP:

• Glial fibrillary tangles: Prominent in olivary neurons
• Hypertrophic olivary degeneration: Trans-synaptic degeneration
• Climbing fiber input loss: Cerebellar ataxia contribution
• Correlation with PSP-P phenotype: More prominent in PSP-P variant

Brainstem Reticular Activating System

Cholinergic Ascending System

The ascending cholinergic pathways from brainstem are compromised:

• Pedunculopontine nucleus (PPN): Degeneration correlates with falls
• Laterodorsal tegmental nucleus (LDT): Contributes to cognitive decline
• Thalamic projection loss: Reduced arousal and attention
• PET imaging: Cholinergic dysfunction correlates with disease stage

Norepinephrine System (LC)

The locus coeruleus shows:

• Severe tau burden: Early involvement in PSP
• Noradrenergic denervation: Detected by MIBG or PET
• Correlation with neuropsychiatric features: Depression, attention deficits
• Therapeutic implication: Alpha-2 agonist effects in PSP

Deep Brain Stimulation Targets in PSP Brainstem

Established and Experimental Targets

| Target | Rationale | Current Status |
|--------|-----------|----------------|
| STN | Excessive output to GPi | DBS performed, mixed results |
| PPN | Gait impairment | Experimental, under investigation |
| Fornix | Memory circuits | Experimental |
| MRF (Midbrain RF) | Arousal and falls | Preclinical |

PPN Deep Brain Stimulation

Recent studies on PPN-DBS in PSP:

• Target: Pedunculopontine nucleus area
• Rationale: Cholinergic output loss causes gait failure
• Outcomes: Mixed — some patients benefit, others show progression
• Biomarkers: Pre-operative PPN activity predicts response

Subthalamic Nucleus DBS

STN-DBS in PSP shows:

• Motor benefits: Tremor, rigidity improvement
• Non-motor symptoms: May worsen cognition
• Careful patient selection: Required for optimal outcomes
• Combined approach: STN + PPN being explored

Preclinical and Translational Models

Canine PSP-Like Tauopathy

Spontaneous canine tauopathy provides brainstem findings:

• 4R-tau predominance: Same as human PSP
• Brainstem involvement: SN, STN pathology similar to PSP
• Age-dependent onset: Natural disease development
• Comparative utility: Non-transgenic model for brainstem mechanisms

Rodent PSP Models

• K369I tau mice: Show brainstem NFT burden
• P301S mice: Reproduce SN and brainstem involvement
• rTg4510: Progressive brainstem neurodegeneration
• 4R-tau knock-in models: Best recapitulate human PSP brainstem

Quantitative Brainstem Staging

Volumetric Disease Staging

| Stage | Midbrain Volume | Clinical Correlation |
|-------|----------------|---------------------|
| Stage 1 | 0-10% loss | Asymptomatic |
| Stage 2 | 10-20% loss | Mild axial symptoms |
| Stage 3 | 20-30% loss | Falls, gait impairment |
| Stage 4 | 30-40% loss | Severe axial, gaze palsy |
| Stage 5 | >40% loss | Bedridden, cognitive decline |

Histological Staging

Brainstem NFT distribution follows a characteristic pattern:

Subthalamic nucleus → first affected

Substantia nigra → early involvement

Locus coeruleus → parallels SN severity

Pontine nuclei → progression pattern

Medulla → late-stage involvement

References

[[An autopsy case of a 76-year-old woman with progressive supranuclear palsy initially presenting with dropped head and clinical features of pure akinesia with gait freezing].](https://pubmed.ncbi.nlm.nih.gov/40399058/) (Rinsho shinkeigaku = Clinical neurology, 2025, PMID:40399058)

[Modeling Sporadic Progressive Supranuclear Palsy in 3D Midbrain Organoids: Recapitulating Disease Features for In Vitro Diagnosis and Drug Discovery.](https://pubmed.ncbi.nlm.nih.gov/39876539/) (Annals of neurology, 2025, PMID:39876539)

[Deep Learning-based Approach for Brainstem and Ventricular MR Planimetry: Application in Patients with Progressive Supranuclear Palsy.](https://pubmed.ncbi.nlm.nih.gov/38506619/) (Radiology. Artificial intelligence, 2024, PMID:38506619)